EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overexpression of lysophospholipid acyltransferase, LPLAT10 / LPCAT4 / LPEAT2 , in the mouse liver increases glucose‐stimulated insulin secretion

Kahori Shimizu iD, Moe Ono, Takenari Mikamoto, Yuya Urayama, Sena Yoshida, Tomomi Hase, Shotaro Michinaga, Hiroki Nakanishi, Miho Iwasaki, Tomoyuki Terada, Fuminori Sakurai, Hiroyuki Mizuguchi iD und 3 weitere

The FASEB Journal · 31.01.2024 · 38 (2)

DOI: 10.1096/fj.202301594rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 16.01.2024. Verfasst von Kahori Shimizu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan. Hauptthemen laut MEDLINE: 1-Acylglycerophosphocholine O-Acyltransferase, Diabetes Mellitus, Type 2, Glucose Intolerance. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, Osaka Ohtani University Research Fundation, National Center for Global Health and Medicine, Intramural Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Postprandial hyperglycemia is an early indicator of impaired glucose tolerance that leads to type 2 diabetes mellitus (T2DM). Alterations in the fatty acid composition of phospholipids have been implicated in diseases such as T2DM and nonalcoholic fatty liver disease. Lysophospholipid acyltransferase 10 (LPLAT10, also called LPCAT4 and LPEAT2) plays a role in remodeling fatty acyl chains of phospholipids; however, its relationship with metabolic diseases has not been fully elucidated. LPLAT10 expression is low in the liver, the main organ that regulates metabolism, under normal conditions. Here, we investigated whether overexpression of LPLAT10 in the liver leads to improved glucose metabolism. For overexpression, we generated an LPLAT10‐expressing adenovirus (Ad) vector (Ad‐LPLAT10) using an improved Ad vector. Postprandial hyperglycemia was suppressed by the induction of glucose‐stimulated insulin secretion in Ad‐LPLAT10‐treated mice compared with that in control Ad vector‐treated mice. Hepatic and serum levels of phosphatidylcholine 40:7, containing C18:1 and C22:6, were increased in Ad‐LPLAT10‐treated mice. Serum from Ad‐LPLAT10‐treated mice showed increased glucose‐stimulated insulin secretion in mouse insulinoma MIN6 cells. These results indicate that changes in hepatic phosphatidylcholine species due to liver‐specific LPLAT10 overexpression affect the pancreas and increase glucose‐stimulated insulin secretion. Our findings highlight LPLAT10 as a potential novel therapeutic target for T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

1-Acylglycerophosphocholine O-AcyltransferaseDiabetes Mellitus, Type 2Glucose IntoleranceAnimalsMiceGlucoseInsulin SecretionLiverPhosphatidylcholinesPhospholipids

Stichwörter der Autor:innen

LPLAT10adenovirus vectordiabetes mellitusglucose-stimulated insulin secretionlysophospholipid acyltransferasephospholipid

Substanzen

1-Acylglycerophosphocholine O-AcyltransferaseGlucosePhosphatidylcholinesPhospholipidsLpcat4 protein, mouse

Autor:innen und Institutionen

  • Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
  • Laboratory of Molecular Biology, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
  • Department of Pharmacodynamics, Meiji Pharmaceutical University, Tokyo, Japan.
  • Lipidome Lab Co., Ltd, Akita, Japan.
  • Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
  • Global Center for Medical Engineering and Informatics, Osaka University, Osaka, Japan.

ORCID-Profile: Kahori Shimizu, Hiroyuki Mizuguchi, Hideo Shindou

Förderung

  • JSPS KAKENHI
  • Osaka Ohtani University Research Fundation
  • National Center for Global Health and Medicine, Intramural Research Fund
  • National Center for Global Health and Medicine

Zitieren

APA

Shimizu, K., Ono, M., Mikamoto, T., Urayama, Y., Yoshida, S., Hase, T., Michinaga, S., Nakanishi, H., Iwasaki, M., Terada, T., Sakurai, F., Mizuguchi, H., Shindou, H., Tomita, K., & Nishinaka, T. (2024). Overexpression of lysophospholipid acyltransferase, LPLAT10 / LPCAT4 / LPEAT2 , in the mouse liver increases glucose‐stimulated insulin secretion. The FASEB Journal, 38(2). https://doi.org/10.1096/fj.202301594rr

Vancouver

Shimizu K, Ono M, Mikamoto T, Urayama Y, Yoshida S, Hase T, et al. Overexpression of lysophospholipid acyltransferase, LPLAT10 / LPCAT4 / LPEAT2 , in the mouse liver increases glucose‐stimulated insulin secretion. The FASEB Journal. 2024;38(2). doi:10.1096/fj.202301594rr

BibTeX
@article{Shimizu2024,
  author = {Shimizu, Kahori and Ono, Moe and Mikamoto, Takenari and Urayama, Yuya and Yoshida, Sena and Hase, Tomomi and Michinaga, Shotaro and Nakanishi, Hiroki and Iwasaki, Miho and Terada, Tomoyuki and Sakurai, Fuminori and Mizuguchi, Hiroyuki and Shindou, Hideo and Tomita, Koji and Nishinaka, Toru},
  title = {Overexpression of lysophospholipid acyltransferase, LPLAT10 / LPCAT4 / LPEAT2 , in the mouse liver increases glucose‐stimulated insulin secretion},
  journal = {The FASEB Journal},
  year = {2024},
  volume = {38},
  number = {2},
  doi = {10.1096/fj.202301594rr}
}
Kostenlos starten →